The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1

BACKGROUND: Heat shock protein 90 (HSP90) inhibitors have emerged as a promising class of anti-cancer drugs in both solid and hematologic malignancies. The HSP90 family includes the cytosolic HSP90 (HSP90AA1), the ER paralogue gp96 (HSP90B1) and the mitochondrial member TRAP1 (HSP90L). We evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Usmani, Saad Z, Bona, Robert D, Chiosis, Gabriela, Li, Zihai
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974653/
https://www.ncbi.nlm.nih.gov/pubmed/20977755
http://dx.doi.org/10.1186/1756-8722-3-40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974653/
https://www.ncbi.nlm.nih.gov/pubmed/20977755
http://dx.doi.org/10.1186/1756-8722-3-40

Ejemplares similares